公开(公告)号：US20220152175A1

公开(公告)日：2022-05-19

申请号：US17592573

申请日：2022-02-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  G01N33/68 ,  C07K14/47 ,  C07K16/30 ,  C07K14/725 ,  C12N5/0783 ,  C12Q1/6886 ,  C12N15/115 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220143162A1

公开(公告)日：2022-05-12

申请号：US17581049

申请日：2022-01-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  C12N15/115 ,  G01N33/574 ,  C07K14/725 ,  G01N33/68 ,  C07K14/47 ,  C07K16/30 ,  C12Q1/6886 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190322715A1

公开(公告)日：2019-10-24

申请号：US16504126

申请日：2019-07-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Valentina GOLDFINGER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  C12N15/62 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C12N15/115 ,  C07K14/74

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190275131A1

公开(公告)日：2019-09-12

申请号：US16385221

申请日：2019-04-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  G01N33/68 ,  G01N33/574 ,  C12Q1/6886 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  C12N15/115 ,  C07K14/725

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190091311A1

公开(公告)日：2019-03-28

申请号：US16210330

申请日：2018-12-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  G01N33/574 ,  G01N33/68 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  A61K38/00

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C07K2319/00 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N33/5748 ,  G01N33/6848 ,  G01N2570/00 ,  G01N2800/52

Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

公开(公告)号：US20250074961A1

公开(公告)日：2025-03-06

申请号：US18947499

申请日：2024-11-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Valentina GOLDFINGER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K39/00 ,  C07K7/06 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12N15/62 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240016908A1

公开(公告)日：2024-01-18

申请号：US18451216

申请日：2023-08-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  C12N5/0783 ,  C07K14/725

CPC classification number: A61K39/4632 ,  C12N5/0636 ,  C07K14/7051 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55527

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220242925A1

公开(公告)日：2022-08-04

申请号：US17716026

申请日：2022-04-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Valentina GOLDFINGER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C12N15/115 ,  C07K14/74 ,  C12N15/62

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220143163A1

公开(公告)日：2022-05-12

申请号：US17581054

申请日：2022-01-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  C12N15/115 ,  G01N33/574 ,  C07K14/725 ,  G01N33/68 ,  C07K14/47 ,  C07K16/30 ,  C12Q1/6886 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220125902A1

公开(公告)日：2022-04-28

申请号：US17576185

申请日：2022-01-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.